相关实验视频
Updated: May 10, 2025

10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
8.7K
在克罗恩氏病中使用新的介质素-23对手
Laura Biskup1, Jan Semeradt1, Jagoda Rogowska1
1Department of Digestive Tract Diseases, Medical University of Lodz, 90-419 Lodz, Poland.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
概括
新的IL-23抑制剂,如Risankizumab,Guselkumab和Mirikizumab,在克罗恩氏病 (CD) 的治疗中显示出显著的有效性和安全性. 这些疗法为中度至重症病例提供临床缓解和内镜治疗,包括那些对其他疗法有抗性的病例.
科学领域:
- 胃肠道学和免疫学
- 炎症性肠道疾病研究研究
- 生物疗法 生物疗法
背景情况:
- 克罗恩氏病 (CD) 是一种与免疫失调相关的慢性炎症状况,因特乐金-23 (IL-23) 是一种关键的促炎细胞因子.
- 目前的治疗方法旨在控制炎症,但中度至重度CD的部分患者,特别是对抗TNF疗法耐药的患者,需要新的方法.
研究的目的:
- 审查选择性IL-23p19抑制剂在克罗恩病管理中的疗效,安全性和治疗潜力.
- 在CD患者中评估risankizumab,guselkumab和mirikizumab的临床和内镜结局.
- 评估这些向治疗的安全性和长期前景.
主要方法:
- 对克罗恩病中IL-23抑制剂的临床试验数据的系统审查.
- 对诱导临床缓解和内镜治疗的疗效的分析.
- 评估安全数据,包括不良事件和长期结果.
主要成果:
- 瑞桑基祖马布,古塞尔库马布和米里基祖马布在中度至重度CD的临床缓解和内镜愈合方面表现出显著的有效性.
- 这些药物对先前接受过抗TNF治疗的患者有效.
- 观察到有利的安全性概况,严重不良事件的发病率较低,如感染和恶性瘤.
结论:
- 选择性IL-23p19抑制剂代表了适度至重度克罗恩病的有针对性和有效的治疗选择.
- 这些新型药物具有较高的临床和内镜缓解率,并具有良好的安全性.
- 对长期疗效和基于生物标志物的患者选择进行进一步的研究是个性化治疗策略的必要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
T Cell Types and Functions
617
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
617

